Sugi Predict

Sugi Predict / Compounds / SCHEMBL16738853

SCHEMBL16738853

SCHEMBL16738853

COc1ccc(Br)c(F)c1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 4/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ POLB P06746 2/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ CTDSP1 Q9GZU7 1/20 0.49
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.43
▸ HTT P42858 1/20 0.40
▸ MAPT P10636 3/20 0.39
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2A Q12879 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ GRIN2C Q14957 1/20 0.39
▸ GRIN3A Q8TCU5 1/20 0.39
▸ ERN1 O75460 1/20 0.39
▸ PKM P14618 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30673293 1.00 TDP1 (0.49) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL2494137 0.85 TDP1 (0.51) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL30439274 0.85 TDP1 (0.51) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL25411924 0.82 ALDH1A1 (0.37) TDP1ALDH1A1MAPTGRIN2DGRIN3B
SCHEMBL593690 0.81 TDP1 (0.49) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL31180316 0.80 TDP1 (0.47) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL21487389 0.80 TDP1 (0.51) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL21624339 0.80 TDP1 (0.47) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL31180312 0.80 TDP1 (0.47) TDP1KDM4EPOLBL3MBTL1CTDSP1
SCHEMBL25280185 0.80 TDP1 (0.51) TDP1KDM4EPOLBL3MBTL1CTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116535304-B Erianin analogue, and synthetic method and application thereof 中国科学院成都生物研究所 2024-07-19 — — CN claimed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-20260059936-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-02-26 — — US disclosed
US-20260047334-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-02-12 — — US disclosed
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-20250338707-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2025-10-30 — — US disclosed
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 — — US disclosed
WO-2025104230-A1 BENZOXAZOLES AS MODULATORS OF IL-17A SANOFI (FR) 2025-05-22 — — WO disclosed
CN-119698416-A Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors 英特莱治疗公司 2025-03-25 — — CN disclosed
EP-4518974-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-12 — — EP disclosed
US-20170014418-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION 2017-01-19 — — US disclosed
US-20170014418-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION 2017-01-19 — — US disclosed
US-9399640-B2 Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors INCYTE CORPORATION (US) 2016-07-26 — — US disclosed
US-9399640-B2 Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors INCYTE CORPORATION (US) 2016-07-26 — — US disclosed
US-9399640-B2 Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors INCYTE CORPORATION (US) 2016-07-26 — — US disclosed
WO-2015081203-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-06-04 — — WO disclosed
WO-2015081203-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-06-04 — — WO disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260047334-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, LDLR, OXER1 TDP1 4370/4885KDM4E 3832/4885POLB 1648/4885
US-20170014418-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 TDP1 2081/4885KDM4E 1518/4885POLB 1091/4885
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS RIPK2, RIPK1, RIPK4 TDP1 938/4885KDM4E 2041/4885POLB 3280/4885
US-20260059936-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, GLRB, GLRA1 TDP1 4760/4885KDM4E 3943/4885POLB 1760/4885
US-20250338707-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, ODC1 TDP1 2958/4885KDM4E 2034/4885POLB 2383/4885
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 TDP1 2081/4885KDM4E 1518/4885POLB 1091/4885
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G TDP1 3192/4885KDM4E 3277/4885POLB 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.